ORIGINAL ARTICLE

Measures of birth size in relation to risk of prostate cancer: the Malmö Diet and Cancer Study, Sweden

P. H. Lahmann[1,2]*, P. Wallström[3], L. Lissner[4], H. Olsson[5] and B. Gullberg[3]

[1]*Population Health Department, Cancer and Population Studies, Queensland Institute of Medical Research, Brisbane, Queensland, Australia*
[2]*Department of Clinical Sciences, Experimental Cardiovascular Research, Lund University, Malmö, Sweden*
[3]*Department of Clinical Sciences, Nutrition Epidemiology Research Group, Lund University, Malmö, Sweden*
[4]*Department of Public Health and Community Medicine, University of Gothenburg, Gothenburg, Sweden*
[5]*Department of Clinical Sciences, Cancer Epidemiology, Division V, Lund University, Lund, Sweden*

There is some evidence that perinatal factors, specifically birth weight (BW), may be related to the onset of prostate cancer (PRCA). This case–control study, nested within the Malmö Diet and Cancer Cohort Study, used archived birth record data from 308 incident PRCA cases diagnosed between 1991 and 2005, and 637 age-matched controls among 4781 men born (1923–1945) in Malmö and Lund, Sweden. We applied conditional logistic regression to examine the birth size–PRCA association, including tumour subtypes, adjusting for perinatal and adult factors. Compared with controls, cases had a non-significantly higher mean BW and were more likely to have high (>4000 g) BW (21% v. 18%), but did not differ in other birth size measures, nor in mean adult body mass index. We observed a non-linear association between BW and PRCA risk. Compared with BWs between 3000 and 3500 g (reference), the fully adjusted odds ratios (OR, 95% CI) were 0.55 (0.33–0.91) for <3000 g, 0.86 (0.61–1.22) for 3500–4000 g and 0.98 (0.64–1.50) for >4000 g. Among men with aggressive tumours, the reduction in risk for those with BWs <3000 g (OR 0.26, 95% CI 0.09–0.72) was stronger than the rate of risk for PRCA overall. Crude risk estimates were minimally attenuated when adjusted for gestational age, maternal age, birth order and adult factors. Birth length, head circumference and placental weight were not associated with prostate cancer. Our results indicate a protective effect of lower BW on risk of total and aggressive prostate cancer, rather than any direct effect of larger birth size.

Introduction

Prostate cancer (PRCA) is the second most common cancer in men worldwide, with a very large population variation in incidence. Age, ethnicity and heredity have been identified as risk factors,[1–3] but much of the aetiology of PRCA remains unclear. PRCA is a hormone-dependent cancer, and, as in breast cancer,[4,5] early life factors, specifically the intrauterine period and prenatal hormonal exposure, have been proposed to be related to PRCA in adult life.[6] Early *in utero* exposure to oestrogen and testosterone, which could influence the hypothalamic–pituitary–testicular feedback system through imprinting, have been proposed to be of aetiologic importance for PRCA.[7,8]

Birth weight (BW), a surrogate measure of foetal growth, and a marker for the intrauterine oestrogen environment,[9] has been the most commonly examined birth size measure in relation to PRCA. The evidence to date, however, does not support a strong association between larger birth size and onset of PRCA despite a growing number of investigations

evaluating this association since the initial record linkage studies from Sweden.[10–12] The earliest of these studies,[12] based on only 21 cases, found a strong positive association between BW and incident PRCA. Most of the subsequent larger studies (eight prospective, one case-control) found a non-significant positive association between BW and overall PRCA risk,[10,13–16] no association[11,17] or even an inverse association.[18] A recent report from the Swedish population-based study of men born in 1913, including 240 cases,[19] showed a significant increase in both PRCA incidence and mortality with high BW and thus confirming their previous results.[12]

Some findings suggest that the birth size–PRCA association is stronger among cases with aggressive PRCA[15,16] or with fatal PRCA.[10] Few of the published studies have examined other birth size indicators such as birth length, head circumference or placental weight in relation to PRCA.[11,15,17,18] As BW appears to be directly associated with adult body mass index (BMI) in almost all studies[20,21] and anthropometric measures of adult body size have been shown to be positively associated with PRCA risk, although not consistently,[22–24] attained BMI may mediate the BW–PRCA association.

In this population-based nested case–control study, we examined recorded BW and other measures of birth size,

*Address for correspondence: Dr P. H. Lahmann, Cancer and Population Studies, Queensland Institute of Medical Research, 300 Herston Road, Herston, Brisbane, Queensland 4006, Australia.
(Email plahmann@gmx.de)

adjusted for gestational age, in relation to total, aggressive and non-aggressive PRCA controlling, first, for selected perinatal and adult factors and, second, for attained BMI measured prior to diagnosis to examine whether the BW–PRCA association is independent of adult body size.

Material and methods

Study population

This case–control study was nested within the population-based Malmö Diet and Cancer (MDC) Cohort Study, a collaborative centre of the European Prospective Investigation into Cancer and Nutrition (EPIC),[25] using available birth record data from 308 incident PRCA cases diagnosed between 1991 and 2005 and 637 age-matched controls. The background population of the MDC study[26] comprises all men born in 1923–1945 and all women born in 1923–1950 who were living in Malmö, Sweden's third largest city, during the recruitment and examination period 1991–1996 ($n = 74,138$). This population was identified through national population registries, the final cohort consisting of 11,063 men and 17,035 women (participation rate 41%). Participants were recruited through invitation by mail and advertisements in local media.[26] Lack of Swedish language skills was the only exclusion criterion. Selection bias has been assessed[27] and indicated that the MDC cohort is representative with regard to obesity and the sociodemographic profile, although it is likely to be selected toward better subjective health.

The present analysis was restricted to PRCA incidence among 4781 men born in the cities of Malmö and Lund aged 46–73 years at study enrolment between January 1991 and September 1996. Only singleton births were included. Prevalent PRCA cases were a priori excluded. Cases were individually matched with controls (1:2) by age (1-year age bands) at enrolment of the MDC study. Because of exclusion of twin births and this leading to an uneven number of controls, some cases were matched 1:1 ($n = 8$) or 1:3 ($n = 20$). Cases were ascertained by record linkage with regional and national cancer registries and defined according to the International Classification of Diseases (ICD) 7th version code 177 and corresponding codes in later ICD versions. Additional data on tumour stage and grade, pre-diagnostic serum prostate-specific antigen (PSA) value, were obtained from the National Prostate Cancer Register (NPCR). Classification by aggressiveness based on stage and grade for the MDC study has been reported earlier.[24,28] An aggressive case was defined as a tumour with one of the following characteristics: a clinical T stage of 3 or higher or tumour-positive lymph nodes (N1) or one or more distant metastases (M1) or a Gleason score of 8 or higher or a pre-treatment serum PSA value of at least 50 ng/ml; tumours were also classified as aggressive if the WHO grade was 3 and Gleason score was unavailable. In cases in which at least two of T stadium, Gleason score or PSA serum value were reported, and if none of these factors indicated an aggressive tumour, the tumour was classified as non-aggressive. Staging/grading data were unavailable or insufficient for five of the cases, leaving 303 cases for the stratified subanalysis on aggressive ($n = 114$)/non-aggressive ($n = 189$) PRCA.

Variables

We abstracted birth characteristics and maternal information from archived hospital delivery records in Malmö and Lund (Regional Archive in Scania, Sweden) using the civil registration number of the mother, which was available through record linkage to the subject. Gestational age was estimated by using information on last menstrual period and delivery date, and ponderal index (PI, g/cm^3) was calculated from recorded data on BW and length. Information on parental occupation, a marker of socioeconomic status (SES) at origin, and adult characteristics, specifically educational level, own occupation and BMI (kg/m^2) based on measured weight (kg) and height (cm) were obtained from the database of the cohort entry examination (1991–1996). Parental and own occupation was classified according to the Nordic Occupation Classification System[29] as follows: unskilled manual worker, skilled manual, low/middle/high non-manual worker, and combined group of farmers, employers, self-employed and missing (unknown). Categories of parental occupation were collapsed further owing to small numbers in some classes. The MDC study and the nested study were both approved by the Ethics Committee at Lund University, Sweden, and participants' informed consent was obtained.

Statistical analysis

We used conditional logistic regression analysis to examine the effect of BW and other birth measures on total PRCA risk. To examine the effects by cancer subtype, we repeated all analyses in strata of men who presented aggressive cancer (38%) and non-aggressive cancer (62%). Multivariable models included adjustment for perinatal factors, gestational age (<36, 36, 37, 38, 39, 40, 41, ≥42 weeks), maternal age (continuous), birth order (1, 2, 3, ≥4), parental occupation (low, medium, high, combined group) and additionally later life factors, namely own educational attainment (≤8, 9–12, >12 years), own occupation (unskilled manual worker, skilled manual, low/middle/high non-manual worker and combined group) and adult BMI (continuous). In complementary analyses, we alternatively examined weight (continuous) and height (continuous) in the fully adjusted model. Place of birth (Malmö, 74%; Lund, 26%) and birth year (categorical, <1925, 1925–1930, 1931–35, 1936–40, 1941–45) were not significantly associated with BW (unadjusted or adjusted for gestational age), nor did the adjustment for place of birth or birth year change the risk estimates in the multivariable adjusted models. Therefore, we did not include these variables in our final analyses. To minimize loss of data in the multivariable analysis, we grouped offspring with missing data on gestational age (2.6%) as term

Table 1. *Perinatal and adult characteristics by prostate cancer status, Malmö Diet and Cancer Study* (n = 945)

Characteristic	Controls (*n* = 637)	Cases (*n* = 308)
	Mean (S.D.)	
Birth weight (g)	3534 (539)	3583 (526)
Birth length (cm)	51.7 (2.5)	51.8 (2.4)
Head circumference[a]	35.5 (1.6)	35.5 (1.5)
Ponderal index (g/cm^3)	25.5 (2.7)	25.7 (3.0)
Placental weight[a] (g)	638 (135)	640 (134)
BMI (kg/m^2) at cohort entry[b]	26.4 (3.6)	26.2 (3.5)
Age (years) at cohort entry[b]	61.3 (6.6)	61.0 (6.6)
Age (years) at diagnosis	–	68.4 (6.0)
	n (%)	
Birth year		
≤1925	86 (13.5)	41 (13.3)
1926–30	202 (31.7)	91 (29.5)
1931–35	150 (23.5)	77 (25.0)
1936–40	109 (17.1)	57 (18.5)
1941–45	90 (14.1)	42 (13.6)
Gestational age (weeks)[a]		
<36	28 (4.4)	10 (3.5)
36	23 (3.6)	12 (4.2)
37	37 (5.9)	18 (6.2)
38	91 (14.4)	33 (11.4)
39	148 (23.5)	62 (21.5)
40	161 (25.5)	88 (30.4)
41	88 (13.9)	40 (13.8)
≥42	55 (8.7)	26 (9.0)
Maternal age (years)		
<20	28 (4.4)	14 (4.5)
20–24	136 (25.6)	82 (26.6)
25–29	192 (30.1)	91 (29.5)
30–34	151 (23.7)	63 (20.5)
≥35	103 (16.2)	58 (18.8)
Birth order[a]		
1	299 (47.1)	134 (44.4)
2	173 (27.2)	83 (27.5)
3	80 (12.6)	37 (12.3)
≥4	83 (13.1)	48 (15.9)
Parental occupation[c]		
Low	175 (27.5)	85 (27.6)
Medium	208 (32.7)	88 (28.6)
High	53 (8.3)	32 (10.4)
Combined group/unknown[d]	201 (31.6)	103 (33.4)
Own educational attainment		
≤8 years	298 (47)	154 (50)
9–12 years	218 (34)	92 (30)
>12 years, university degree	121 (19)	62 (20)
Own occupation		
Unskilled manual worker	86 (13.5)	50 (16.2)
Skilled manual	104 (16.3)	51 (16.6)
Low non-manual worker	124 (19.5)	53 (17.2)
Middle non-manual worker	134 (21.0)	63 (20.5)

Table 1. *Continued*

Characteristic	Controls (*n* = 637)	Cases (*n* = 308)
High non-manual worker	75 (11.8)	39 (12.7)
Combined group/unknown[d]	114 (17.9)	52 (16.9)

BMI, body mass index.
[a] Percentages are of non-missing data. Numbers may not sum to 100% due to rounding and missing data on birth length (1), ponderal index (*n* = 1), head circumference (*n* = 57), placental weight (*n* = 4), gestational age (*n* = 25) and birth order (*n* = 8).
[b] Start of follow-up (1991–1996).
[c] Low (unskilled manual worker), medium (skilled manual and low non-manual worker), high (middle and high non-manual worker), combined group/unknown: including farmers, employers, self-employed, missing data.
[d] Combined group/unknown: including farmers, employers, self-employed, missing data.

births (39 weeks), after scrutinizing their BWs. Results from additional sensitivity analyses were not changed when births with missing gestational age were excluded. We modelled BW as continuous variable (by 100 g) and as categorical one (<3000 g, 3000–3499 g (reference), 3500–3999 g, >4000 g) to be able to detect non-linear effects. We categorized birth length (cm) and head circumference (cm) into five and four approximately equal groups, and used quartiles for placental weight (g) and PI. Missing data were generally low (≤6%) for these birth size measures. All tests of statistical significance were two sided, and *P*-values <0.05 were considered statistically significant. Analyses were performed using the IBM SPSS Statistics 19 (IBM Corporation, Armonk, NY, USA) and SAS Statistical Software, version 9.2 (SAS Institute, Cary, NC, USA).

Results

Mean (± S.D.) BW and gestational age were 3550 ± 535 g and 39.3 ± 2.0 weeks, respectively. BW did not substantially differ by birth time period, that is, by 5-year birth year intervals between 1923 and 1945 (data not shown). BW was positively correlated with maternal age (*r* = 0.16), birth order (*r* = 0.24), adult weight (*r* = 0.12) and height (*r* = 0.21; all *P* < 0.01), but was not correlated with BMI. BW was not related to early (parental occupation) and adult (own occupation or education) SES.

Table 1 shows the characteristics of study participants by case status. Cases had a statistically non-significantly higher mean BW than controls (3583 g, CI 3523–3641 g *v.* 3534 g, CI 3491–3575 g), were more likely to have high BW (>4000 g) than controls (21% *v.* 18%) and less likely to have BW <3000 g (9% *v.* 15%). The proportion of offspring with BW <3000 g was slightly lower in aggressive cancer cases (7%) than in non-aggressive cancer cases (11%). Cases did not differ from controls with regard to BMI and SES

Table 2. *ORs and 95% CIs for total, aggressive and non-aggressive PRCA by BW, Malmö Diet and Cancer Study* (n = 945)

BW	Cases	Model 1: crude[a]		Model 2: adjusted for perinatal and adult factors[b]		Model 3: further adjusted for adult BMI[c]	
		OR	95% CI	OR	95% CI	OR	95% CI
		Total PRCA					
BW continuous (100 g)	308	1.02	0.99–1.04	1.02	0.99–1.05	1.02	0.98–1.05
		$P = 0.193$		$P = 0.305$		$P = 0.285$	
Categorical (g)							
<3000	29	0.56	0.35–0.90	0.55	0.33–0.91	0.55	0.33–0.91
3000–3500	99	Reference		Reference		Reference	
3500–4000	116	0.85	0.61–1.19	0.85	0.60–1.20	0.86	0.61–1.22
>4000	64	0.99	0.66–1.47	0.96	0.63–1.48	0.98	0.64–1.50
		$P = 0.091$		$P = 0.122$		$P = 0.133$	
		Aggressive PRCA[d]					
BW continuous (100 g)	114	1.01	0.97–1.06	1.00	0.94–1.05	1.00	0.94–1.06
		$P = 0.568$		$P = 0.938$		$P = 0.933$	
Categorical (g)							
<3000	8	0.29	0.11–0.72	0.28	0.10–0.78	0.26	0.09–0.72
3000–3500	44	Reference		Reference		Reference	
3500–4000	37	0.46	0.26–0.83	0.39	0.21–0.74	0.38	0.20–0.73
>4000	25	0.69	0.36–1.33	0.62	0.29–1.36	0.63	0.29–1.39
		$P = 0.015$		$P = 0.012$		$P = 0.009$	
		Non-aggressive PRCA[d]					
BW continuous (100 g)	189	1.02	0.99–1.06	1.03	0.99–1.07	1.03	0.99–1.08
		$P = 0.222$		$P = 0.136$		$P = 0.128$	
Categorical (g)							
<3000	20	0.81	0.45–1.47	0.76	0.40–1.45	0.76	0.40–1.49
3000–3500	53	Reference		Reference		Reference	
3500–4000	78	1.28	0.83–1.98	1.37	0.87–2.17	1.41	0.89–2.25
>4000	38	1.22	0.72–2.05	1.30	0.74–2.30	1.32	0.75–2.34
		$P = 0.382$		$P = 0.259$		$P = 0.237$	

OR, odds ratio; CI, confidence interval; PRCA, prostate cancer; BW, birth weight; BMI, body mass index.

[a] Model 1: crude, unadjusted.

[b] Model 2: adjusted for gestational age (categorical), maternal age (continuous), birth order (categorical), parental occupation (categorical), educational attainment (categorical), own occupation (categorical).

[c] Model 3: adjusted for factors in Model 2, and additionally for adult BMI (continuous).

[d] Aggressive PRCA ($n = 114$) and non-aggressive PRCA ($n = 189$) due to missing information on subtype in 5 out of 308 cases.

indicators (parental/own occupation, own education), nor in any other birth size indicator. Median age at diagnosis of PRCA was 68 years (range 51–81).

When BW was fitted as a continuous term, we observed a 2% increase in risk with each increment of 100 g [fully adjusted model: odds ratio (OR) 1.02, 0.98–1.05; $P = 0.35$] for total PRCA, indicating that risk did not increase in a linear manner with increasing BW (Table 2). When using categorical BW, men who weighed under 3000 g at birth had a 45% decreased risk of PRCA (multivariate OR 0.55, 0.33–0.91) compared with men with BW between 3000 and 3500 g (reference). Higher BW (3500–3999 g, >4000 g) was not associated with risk of total PRCA. The crude risk estimates were only marginally attenuated when adjusted for perinatal

and adult factors. Using weight and height (both continuous) instead of BMI in the fully adjusted model did not change the OR from the model with BMI (data not shown).

The non-linear relationship between BW and risk of PRCA was limited to those with aggressive PRCA (Table 2). When compared with men with reference BW, BW <3000 g was associated significantly with reduced risk of cancer (fully adjusted OR 0.26, 95% CI 0.09–0.72). Further, men with BW between 3500 and 4000 g had a substantially reduced risk of aggressive tumours (OR 0.38, 95% CI 0.20–0.73) compared with those with BW between 3000 and 3500 g. In contrast, among men with non-aggressive tumours, higher BW (>3500 g) appeared to be associated with increased risk of cancer, but ORs did not significantly vary from unity.

Table 3. *ORs and 95% CIs for total prostate cancer by other birth size indicators, Malmö Diet and Cancer Study (*n = 945*)*

Measure	Cases	Model 1: crude[a]		Model 2: adjusted for perinatal and adult factors[b]		Model 3: further adjusted for adult BMI[c]	
		OR	95% CI	OR	95% CI	OR	95% CI
Birth length (cm; categorical)[d]							
≤50	90	Reference		Reference		Reference	
51	57	1.11	0.72–1.73	1.05	0.66–1.66	1.03	0.65–1.64
52	63	1.47	0.98–2.21	1.47	0.97–2.24	1.47	0.96–2.24
53	42	0.96	0.61–1.49	0.92	0.57–1.47	0.90	0.56–1.45
≥54	65	1.00	0.67–1.49	0.94	0.61–1.44	0.94	0.61–1.44
Trend *P*-value		0.968		0.769		0.768	
Head circumference (cm; categorical)[d]							
≤34	71	Reference		Reference		Reference	
35	69	0.97	0.65–1.44	0.98	0.64–1.51	0.99	0.65–1.52
36	83	1.05	0.71–1.55	1.00	0.66–1.52	1.00	0.66–1.53
≥37	67	1.16	0.77–1.76	1.06	0.68–1.67	1.06	0.68–1.67
Trend *P*-value		0.463		0.790		0.780	
Ponderal index (g/cm³; quartiles)[d]							
<23.7	76	Reference		Reference		Reference	
23.7–25.4	80	1.08	0.72–1.61	1.05	0.70–1.58	1.06	0.71–1.60
25.4–27.4	71	0.91	0.60–1.36	0.85	0.55–1.29	0.85	0.56–1.31
≥27.5	80	1.10	0.71–1.70	1.04	0.66–1.64	1.05	0.67–1.66
Trend *P*-value		0.889		0.883		0.922	
Placental weight (g; quartiles)[d]							
<550	64	Reference		Reference		Reference	
550–630	87	1.17	0.79–1.74	1.15	0.76–1.74	1.16	0.77–1.74
630–710	78	1.08	0.72–1.61	1.06	0.70–1.60	1.09	0.72–1.64
≥710	76	1.11	0.74–1.68	1.08	0.70–1.66	1.10	0.72–1.70
Trend *P*-value		0.756		0.878		0.807	

OR, odds ratio; CI, confidence interval; BMI, body mass index.

[a] Model 1: crude, unadjusted.

[b] Model 2: adjusted for gestational age (categorical), maternal age (continuous), birth order (categorical), parental occupation (categorical), educational attainment (categorical), occupation (categorical).

[c] Model 3: adjusted for factors in Model 2, and additionally for adult BMI (continuous).

[d] Missing data: birth length (*n* = 1), head circumference (*n* = 57), ponderal index (*n* = 1), placental weight (*n* = 4).

We examined other birth characteristics in relation to PRCA (Table 3). Birth length, head circumference, PI and placental weight were not associated with risk of total PRCA, aggressive or non-aggressive tumours.

Discussion

In this large nested case–control study of Swedish men born between 1923 and 1945 in the cities of Malmö and Lund, we observed a significantly decreased risk of total PRCA for men with BW below 3000 g when compared with men with BW between 3000 and 3500 g (reference) accounting for other perinatal factors and adult body size. Higher BW (>3500 g) was not associated with total PRCA risk. Results from our cancer subtype analysis indicate that the protective effect of BW below 3000 g became particularly apparent in men who presented with aggressive tumours. Notably, among men with

this subtype, risk of cancer was also substantially reduced in those who were born with a BW between 3500 and 4000 g when compared with the referent. We found no evidence that other birth size indicators had an effect on risk of total PRCA or subtypes.

Our finding on BW does not corroborate the majority[10,12–16,19] of previous studies, indicating that larger BW tends to be associated with increased risk of PRCA. In our study, BW <3000 g was associated with a considerable decrease in risk of 45% compared with the reference category (3000–3500 g), and adjusted ORs were slightly reduced for the upper two BW categories. Only one previous report[18] suggested a weak inverse association between BW and PRCA risk. In that US case–control study on early-onset PRCA (cases aged ≤54 years) using similar BW categorization, but with reference category <3000 g, risk for men with BW >4000 g was reduced by 50%. However, this finding was not

confirmed when applied to a second separate control group.[18] As in our study, non-linear associations between BW and PRCA have been demonstrated in previous studies,[13,14,19] yet suggesting excess risk especially among offspring with larger BW.

In the present study, we examined aggressiveness defined by stage and grade of the tumour in relation to birth size. The reduction in risk with BW < 3000 g was larger in men with aggressive tumours ($n = 114$) than in PRCA overall (74% *v.* 45%). The OR was also reduced by 62% for men with BW between 3500 and 4000 g when compared with the referent. In contrast, none of these associations were present with non-aggressive disease. To our knowledge, only two other studies[15,16] investigated aggressiveness of incident PRCA in relation to birth size. Elevated risk estimates with higher BW categories were reported to be slightly stronger for metastatic ($n = 33$)[15] or high stage/grade ($n = 213$)[16] tumours than for overall PRCA. When comparing the highest *v.* the lowest (referent) BW categories, the increase in risk was 50% for metastatic tumours (RR 1.5, 95% CI 0.6–3.7)[15] and 30% for high stage/grade tumours (RR 1.30, 95% CI 0.80–2.10).[16]

The somewhat disparate findings on the BW–PRCA association for total PRCA or tumour subtype, between our study and previous reports, may be partly because of differences in study design and methodology. Direct comparisons between our study and those with a positive exposure–outcome relation are limited because of differences in the categorization of BW and use of reference categories. However, this may not explain the difference in the observed risk pattern in the present study. For instance, findings from the Swedish population-based prospective study of men born in 1913,[19] using a compatible reference group of 'normal' BW as in this study, indicate no effect of BW ≤ 3000 g on risk of overall PRCA, but excess risk (RR 1.62, 95% CI 1.04–2.51) for those men born with high BW (> 4250 g).

Moreover, relevant studies adjusted for different sets of perinatal and adult variables,[11,15–17,19] or not at all.[10,12,13] One study used a special population, that is twins,[14] and the US study of Health Professionals[16] relied on self-reported BW, which is known to be more prone to measurement error than those based on birth records.[5] Furthermore, it has been suggested[4] that the retrospective design of the latter study was likely to mask any decreased risk for PRCA in men with low BW, as it was confined to survivors, and low BW has been associated with elevated cardiovascular mortality.

Adjustment for selected perinatal and maternal characteristics, available indicators of SES, and adult size did not materially change the BW–PRCA association in our study. Specifically, gestational age did not appreciably influence this relationship, which is compatible with another report,[19] and was in itself not associated with PRCA risk (data not shown). The latter finding contrasts two studies that observed an inverse association[11] or a non-significant positive association[17] between 1-week increase in length of gestation and PRCA risk. Similarly, no consistent association between gestational age at birth and risk of breast cancer has been observed.[6,30] In the present study, maternal age and birth order were not related to PRCA. There is only little and inconsistent evidence to date that parental age and birth order are important for PRCA risk.[10,11,15,31,32]

We particularly aimed at examining the impact of adult body size on the association between BW and risk of PRCA, and observed that attained BMI did not mediate this association, nor did weight and height instead of body mass. Higher BMI was not associated with increasing risk of total or subtype PRCA in this nested case–control study and is in concordance with the total cohort of men in the MDC study.[24] Considering our finding and that of others,[19] there seems to be a negligible, if any, impact of attained BMI at midlife or later on the early size–PRCA relationship. This may not be surprising given the rather inconsistent evidence for the association between BMI and PRCA.[22]

In our study, birth length was unrelated to risk of PRCA. In contrast, two previous studies suggested a weak association between birth length and risk of total PRCA,[15,18] but with significant risk estimates only among men with metastatic PRCA in the Norwegian study,[15] despite its small sample size ($n = 33$). Head circumference, PI and placental weight, an important correlate of pregnancy hormone levels, were not related to PRCA in the present study, a finding compatible with few past reports.[10,11,15,17]

Strengths of our study include its prospective design and use of cancer registry data and perinatal information from archived hospital birth records, all of which are reducing potential bias affecting the results. Further, in contrast to previous studies, we were able to adjust for both selected perinatal and adult factors simultaneously, hence minimizing confounding. It cannot be ruled out that some confounding bias is still present, due to the lack of inclusion of other potential risk factors; yet adult risk factors other than family history, information that was not available to us, have not been clearly established for PRCA. Genetic components possibly confound the BW–PRCA association as suggested by a recent twin study.[14] Confounding by SES may not have been captured entirely by the three social indicators included,[33] but residual confounding in this study is less likely an issue compared with others. None of the previous studies, but one,[17] did adjust for SES,[12,13,16,18] or adjusted for parental SES only.[10,11,14,15,19] Although we may have had limited statistical power for the tumour subtype analysis, the observed associations for aggressive tumours were stronger than those reported by others with smaller[15] or larger sample size.[16] Overall, the total number of PRCA cases ($n = 308$) in our study was larger than that for the majority of other investigations,[10,12,13,15,17–19] except for three (cases $n \geq 382$).[11,14,16]

On the basis of the overall inconsistent results of published data to date, the question remains as to how birth size and foetal growth are implicated in PRCA risk. The original hypothesis by Trichopoulos[34] that *in utero* exposure to

estrogens would influence risk of breast cancer has been extended to androgen exposure *in utero* and other hormone-related cancers, including PRCA.[8,11] Experimental data support the hypothesis that perinatal steroid hormone exposure influences the structure and function of the prostate gland.[35] Aside from high maternal oestrogen and testosterone levels, which are both associated with foetal growth and long-term susceptibility to cancer, the insulin-like growth factor-I hormone has been proposed to be of aetiologic importance for birth size and PRCA as reviewed by others.[19] Further, factors that promote foetal growth may alter the number of stem cells and thus influence cancer risk.[36,37] However, it remains to be elucidated how these suggested biological mechanisms operate precisely and specifically, and which part of the BW range is mostly affected.

In conclusion, in this study of Swedish men, we found evidence of a non-linear relationship between BW and PRCA, with strongly decreased risks especially among men with BW <3000 g and those with aggressive disease. Larger birth size (>3500 g) tended to be inversely related to overall PRCA and aggressive subtype. Our findings add to the existing evidence that this cancer in men seems to be influenced by the intrauterine environment, but in contrast to previous reports we observed that small birth size (BW) is related to reduced PRCA risk, rather than large BW being a risk factor. On the basis of our data, there is no support for a role of birth length or other birth size indicators in the development of PRCA. Because of limited statistical power, especially in the tumour subtype analysis, these findings require further replication in studies with larger sample size.

Acknowledgements

References

1. Damber JE, Aus G. Prostate cancer. *Lancet.* 2008; 371, 1710–1721.
2. Nelen V. Epidemiology of prostate cancer. *Recent Results Cancer Res.* 2007; 175, 1–8.
3. Wigle DT, Turner MC, Gomes J, Parent ME. Role of hormonal and other factors in human prostate cancer. *J Toxicol Environ Health B Crit Rev.* 2008; 11, 242–259.
4. Ekbom A. Growing evidence that several human cancers may originate in utero. *Semin Cancer Biol.* 1998; 8, 237–244.
5. Silva Idos S, De Stavola B, McCormack V. Birth size and breast cancer risk: re-analysis of individual participant data from 32 studies. *PLoS Med.* 2008; 5, e193.
6. Potischman N, Troisi R, Vatten LJ. The life course approach to cancer epidemiology. In *A life course approach to chronic disease epidemiology* (eds. Kuh D, Ben-Shlomo Y), 2004; pp. 260–280. New York: Oxford University Press.
7. Henderson BE, Bernstein L, Ross RK, Depue RH, Judd HL. The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. *Br J Cancer.* 1988; 57, 216–218.
8. Ross RK, Henderson BE. Do diet and androgens alter prostate cancer risk via a common etiologic pathway? *J Natl Cancer Inst.* 1994; 86, 252–254.
9. Kaijser M, Granath F, Jacobsen G, Cnattingius S, Ekbom A. Maternal pregnancy estriol levels in relation to anamnestic and fetal anthropometric data. *Epidemiology.* 2000; 11, 315–319.
10. Ekbom A, Hsieh CC, Lipworth L, et al. Perinatal characteristics in relation to incidence of and mortality from prostate cancer. *BMJ.* 1996; 313, 337–341.
11. Ekbom A, Wuu J, Adami HO, et al. Duration of gestation and prostate cancer risk in offspring. *Cancer Epidemiol Biomarkers Prev.* 2000; 9, 221–223.
12. Tibblin G, Eriksson M, Cnattingius S, Ekbom A. High birthweight as a predictor of prostate cancer risk. *Epidemiology.* 1995; 6, 423–424.
13. Ahlgren M, Wohlfahrt J, Olsen LW, Sörensen TI, Melbye M. Birth weight and risk of cancer. *Cancer.* 2007; 110, 412–419.
14. Cnattingius S, Lundberg F, Sandin S, Gronberg H, Iliadou A. Birth characteristics and risk of prostate cancer: the contribution of genetic factors. *Cancer Epidemiol Biomarkers Prev.* 2009; 18, 2422–2426.
15. Nilsen TI, Romundstad PR, Troisi R, Vatten LJ. Birth size and subsequent risk for prostate cancer: a prospective population-based study in Norway. *Int J Cancer.* 2005; 113, 1002–1004.
16. Platz EA, Giovannucci E, Rimm EB, et al. Retrospective analysis of birth weight and prostate cancer in the Health Professionals Follow-up Study. *Am J Epidemiol.* 1998; 147, 1140–1144.
17. McCormack VA, dos Santos Silva I, Koupil I, Leon DA, Lithell HO. Birth characteristics and adult cancer incidence: Swedish cohort of over 11,000 men and women. *Int J Cancer.* 2005; 115, 611–617.
18. Boland LL, Mink PJ, Bushhouse SA, Folsom AR. Weight and length at birth and risk of early-onset prostate cancer (United States). *Cancer Causes Control.* 2003; 14, 335–338.
19. Eriksson M, Wedel H, Wallander MA, et al. The impact of birth weight on prostate cancer incidence and mortality in a population-based study of men born in 1913 and followed up from 50 to 85 years of age. *Prostate.* 2007; 67, 1247–1254.
20. Oken E, Gillman MW. Fetal origins of obesity. *Obes Res.* 2003; 11, 496–506.
21. Rogers I. The influence of birthweight and intrauterine environment on adiposity and fat distribution in later life. *Int J Obes Relat Metab Disord.* 2003; 27, 755–777.
22. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. *Cancer Causes Control.* 2006; 17, 989–1003.

23. Pischon T, Boeing H, Weikert S, *et al*. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev*. 2008; 17, 3252–3261.

24. Wallström P, Bjartell A, Gullberg B, Olsson H, Wirfält E. A prospective Swedish study on body size, body composition, diabetes, and prostate cancer risk. *Br J Cancer*. 2009; 100, 1799–1805.

25. Riboli E, Hunt KJ, Slimani N, *et al*. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *PHN*. 2002; 5, 1113–1124.

26. Berglund G, Elmståhl S, Janzon L, Larsson SA. The Malmo diet and Cancer study. Design and feasibility. *J Intern Med*. 1993; 233, 45–51.

27. Manjer J, Carlsson S, Elmstahl S, *et al*. The Malmo Diet and Cancer Study: representativity, cancer incidence and mortality in participants and non-participants. *Eur J Cancer Prev*. 2001; 10, 489–499.

28. Wallström P, Bjartell A, Gullberg B, Olsson H, Wirfält E. A prospective study on dietary fat and incidence of prostate cancer (Malmo, Sweden). *Cancer Causes Control*. 2007; 18, 1107–1121.

29. Statistics Sweden. *Occupations in Population and Housing Census 1985*, 1985. Statistics Sweden: Stockholm.

30. Lahmann PH, Gullberg B, Olsson H, *et al*. Birth weight is associated with postmenopausal breast cancer risk in Swedish women. *Br J Cancer*. 2004; 91, 1666–1668.

31. Janerich DT, Hayden CL, Thompson WD, Selenskas SL, Mettlin C. Epidemiologic evidence of perinatal influence in the etiology of adult cancers. *J Clin Epidemiol*. 1989; 42, 151–157.

32. Zhang Y, Kreger BE, Dorgan JF, *et al*. Parental age at child's birth and son's risk of prostate cancer. The Framingham Study. *Am J Epidemiol*. 1999; 150, 1208–1212.

33. Lawlor DA, Davey Smith G, Kundu D, Bruckdorfer KR, Ebrahim S. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence? *Lancet*. 2004; 363, 1724–1727.

34. Trichopoulos D. Hypothesis: does breast cancer originate in utero? *Lancet*. 1990; 335, 939–940.

35. Shibata A, Minn AY. Perinatal sex hormones and risk of breast and prostate cancers in adulthood. *Epidemiol Rev*. 2000; 22, 239–248.

36. Johnson KJ, Springer NM, Bielinsky AK, Largaespada DA, Ross JA. Developmental origins of cancer. *Cancer Res*. 2009; 69, 6375–6377.

37. Risnes KR, Vatten LJ, Baker JL, *et al*. Birthweight and mortality in adulthood: a systematic review and meta-analysis. *Int J Epidemiol*. 2011; 40, 647–661.